Posted by Michael Wonder on 28 Jul 2023
Talazoparib tosylate for the treatment of patients with advanced, germline BRCA mutation positive, HER2 negative breast cancer
28 July 2023 - NICE has published preliminary evidence-based recommendations on the use of talazoparib tosylate (Talzenna) for the treatment of adults with locally advanced or metastatic breast cancer.
Talazoparib tosylate is not recommended for the treatment of adults with locally advanced or metastatic, germline BRCA 1/2 mutation positive, HER2 negative breast cancer who have had:
- An anthracycline or a taxane, or both, unless these treatments are not suitable, and
- Endocrine therapy if they have hormone receptor positive breast cancer, unless this is not suitable
